BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

04/08/2020 08:00

Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

27/07/2020 08:00

Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

03/07/2020 08:00

Biophytis announces a € 6.1 million capital increase through private placement

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

01/07/2020 21:05

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

01/07/2020 21:00

Biophytis announces the issuance of a €3 million tranche of ORNANE

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

23/06/2020 08:00

Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

11/06/2020 08:00

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

10/06/2020 08:00

Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

28/05/2020 18:00

Results of the Combined General Meeting of May 28, 2020

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

20/05/2020 08:02

Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure

Voir tous les communiqués de BIOPHYTIS

1
2
3
4
5
6
7
8
9
10
»